Penetrium Bioscience Inc. (KOSDAQ:187660)

Market Cap	575.56B +649.5%
Revenue (ttm)	9.74B -29.3%
Net Income	-20.10B
EPS	-475.02
Shares Out	54.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,729,202
Average Volume	8,000,783
Open	10,880
Previous Close	10,510
Day's Range	10,050 - 10,890
52-Week Range	1,118 - 21,500
Beta	3.02
RSI	42.72
Earnings Date	Mar 30, 2026

About Penetrium Bioscience

Penetrium Bioscience Inc., a contract research organization, provides clinical services in Asia. It offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. The company also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. In addition, it develops, manufactures, and sell...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 160
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187660

Financial Performance

In 2024, Penetrium Bioscience's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.